Recon: Allakos cuts its workforce by 50%, halts lead inflammatory candidate; Takeda wins another FDA approval for immune globulin therapy HyQvia
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States